A Phase 1 interventional study of [14C]VC005 in Atopic Dermatitis, sponsored by Jiangsu vcare pharmaceutical technology co., LTD. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-11.
Sponsored by Jiangsu vcare pharmaceutical technology co., LTD · Phase 1, Interventional, and Treatment
This study was designed to evaluate the mass balance and biotransformation after single-dose of [14C]VC005 orally in Chinese healthy male volunteers.
1,419 studies on the registry are indexed under Dermatitis, Atopic; 258 are open to participants now.
This study's enrollment of 6 is below the median of 83 across 1,125 interventional studies indexed under Dermatitis, Atopic.
Browse Dermatitis, Atopic studies →Jiangsu vcare pharmaceutical technology co., LTD is the lead sponsor of 34 studies on the registry; 12 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: [14C]VC005
Take a suspension of 50 mg VC005 ,containing about 120 μCi \[14C\]VC005, in fasting within 5 minutes
Cumulative excretion rate of radioactivity in urine
Time frame: from 0 hour to 216 hours after administration
Cumulative excretion rate of radioactivity in feces
Time frame: from 0 hour to 216 hours after administration
Total radioactivity
Time frame: from 0 hour to 216 hours after administration
Adverse events
Time frame: From signing the ICF until 10 days after the dosing
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jiangsu vcare pharmaceutical technology co., LTD